Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals
Betsy Goodfellow | April 24, 2024 | News story | Manufacturing and Production | Eli Lilly, Nexus Pharmaceuticals, Pharmacy, acquisition, facility
Eli Lilly and Nexus Pharmaceuticals have announced that they have entered into a definitive agreement for Eli Lilly to acquire a manufacturing facility from Nexus.
The facility is located in Pleasant Prairie, Wisconsin, US, and is already FDA approved. The acquisition is intended to help Eli Lilly’s expansion of its global parenteral (injectable) product manufacturing network as well as supporting the increased demand for the company’s products.
Weil, Gotshal & Manges LLP is acting as Eli Lilly’s legal advisor while Centerview Partners LLC is acting as exclusive financial advisor, and Sullivan & Cromwell LLP as legal counsel to Nexus Pharmaceuticals.
Edgardo Hernandez, executive vice president and president of Lilly manufacturing, commented: “The acquisition of this state-of-the-art facility underscores our unwavering commitment to growth and innovation, and we look forward to welcoming talented new Nexus colleagues to Lilly from the Pleasant Prairie facility. We are investing boldly to serve our patients, to meet product demand and to build capabilities for our robust pipeline of the future.”
Usman Ahmed, president and chief executive officer of Nexus Pharmaceuticals, added: “We are excited Lilly is continuing our family’s mission of providing lifesaving medications to those who need them most. This milestone is a testament to the dedication of our Nexus employees in building a best-in-class injectable manufacturing facility. The combination of our teams and infrastructure with Lilly’s global platform will benefit patients all over the world.”
Betsy Goodfellow
Related Content
Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …
Lilly’s drug for early Alzheimer’s shows promising results
Eli Lilly (Lilly) has announced positive new data from the long-term extension of its phase …
Roche receives CE Mark for blood test to help rule out Alzheimer’s
Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …
